(Total Views: 456)
Posted On: 10/31/2022 9:53:00 AM
Post# of 154119
Cytokines are very fashionable at big pharma. Methinks LL is the sweet spot of cytokine therapy. Patience Bunkyl
"IL-2 has long been notorious as a target. While the cytokine can activate immune cells against cancer, those effects are a double-edged sword, triggering dangerous side effects for patients. Multiple companies have struggled to tread the fine line between safety and efficacy — with Nektar representing the latest and perhaps most high-profile implosion when it shuttered its Bristol Myers Squibb-partnered program.
Sanofi takes $1.6B hit on IL-2
"IL-2 has long been notorious as a target. While the cytokine can activate immune cells against cancer, those effects are a double-edged sword, triggering dangerous side effects for patients. Multiple companies have struggled to tread the fine line between safety and efficacy — with Nektar representing the latest and perhaps most high-profile implosion when it shuttered its Bristol Myers Squibb-partnered program.
Sanofi takes $1.6B hit on IL-2
(3)
(0)
